Sector News

Reuters: Teva poised to raise its stake in Mylan – sources

June 3, 2015
Life sciences
Teva Pharmaceutical Industries Ltd is looking to buy more shares in Mylan NV (MYL.O), positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid, people familiar with the matter said.
 
The strategy is a sign of Teva’s commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Company Plc (PRGO.N).
 
Teva last week disclosed a 1.8 percent stake in Mylan, which blasted the move as breaching U.S. antitrust laws because of the stake’s size. U.S antitrust laws bar companies from acquiring stakes worth more than $76.3 million in rivals without first obtaining regulatory approval. Teva’s stake in Mylan far exceeds that threshold.
 
The dispute boils down to where Mylan, which is incorporated in the Netherlands, has its “principal” offices. Mylan argues these are located within the United States for the purposes of the U.S. Federal Trade Commission, thereby affording it antitrust protection, even as it lists its principal executives offices in Britain in filings with the U.S. Securities and Exchange Commission.
 
Despite this issue, Teva may increase its stake in Mylan to around 4.6 percent, the people said. Such a stake would allow Teva to have standing in Dutch court to potentially challenge Mylan, which has so far refused to engage with its Israeli rival, the people added.
 
Teva may seek to reach this ownership threshold ahead of Mylan’s record date, or the date in which a shareholder must officially own shares to be entitled to vote on the tender offer for Perrigo, they said. This would raise pressure on Mylan’s management ahead of the vote, the people added.
 
A tender offer for Mylan is likely to come after Teva raises its stake, the people said.
 
The sources asked not to be identified because Teva’s deliberations are not public. Representatives for Teva and Mylan declined to comment.
 
Mylan, which makes the EpiPen product for severe allergies, can take advantage of Dutch provisions that would make a hostile takeover difficult because of its incorporation in the Netherlands.
 
Hedge fund Paulson & Co LP in April raised its stake in Mylan to around 4.6 percent, including derivatives, to put pressure on Mylan management to pursue a tie-up with Teva. The hedge fund has been privately encouraging Mylan’s board to consider Teva’s takeover proposal, people previously told Reuters.
 
By Olivia Oran (Additional reporting by Greg Roumeliotis in New York)

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend